Agenus Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
27,352.00
40,224.10
171,667.60
76,436.80
60,186.60
53,053.50
Total Accounts Receivable
1.20
-
9,800.30
11,352.00
1,134.50
938.10
Inventories
-
95.70
88.20
88.20
79.50
55.50
Other Current Assets
821.40
2,350.50
2,539.20
3,435.20
12,153.00
20,760.50
Total Current Assets
28,174.60
42,670.30
184,095.40
91,312.20
73,553.60
74,807.70
Net Property, Plant & Equipment
2,784.80
5,996.70
15,310.60
25,634.00
26,178.60
25,115.60
Intangible Assets
2,572.20
24,642.70
41,552.40
38,757.10
37,455.50
35,263.10
Other Assets
1,303.90
1,216.80
1,270.10
1,282.70
1,214.40
1,214.40
Total Assets
34,835.50
74,526.50
242,228.50
156,986.00
138,402.00
136,400.70
ST Debt & Current Portion LT Debt
3,518.60
1,257.20
146.10
435.10
15,434.70
Accounts Payable
834.70
1,710.90
4,488.60
5,428.50
8,087.00
Other Current Liabilities
5,942.60
6,261.30
24,299.50
34,987.70
32,916.40
Total Current Liabilities
10,295.90
9,229.40
28,934.10
40,851.20
56,438.10
Long-Term Debt
5,347.70
4,769.40
114,326.50
111,720.40
111,396.00
Provision for Risks & Charges
18,799.10
31,699.30
5,608.00
7,561.00
4,373.00
Other Liabilities
4,873.50
5,810.10
22,632.40
35,979.60
42,010.70
Total Liabilities
39,316.20
51,508.10
171,500.90
196,112.30
214,217.80
Common Equity (Total)
4,481.10
23,018.10
70,727.20
39,126.60
75,816.10
Total Shareholders' Equity
4,480.70
23,018.40
70,727.60
39,126.30
75,815.80
Total Equity
4,480.70
23,018.40
70,727.60
39,126.30
75,815.80
Liabilities & Shareholders' Equity
34,835.50
74,526.50
242,228.50
156,986.00
138,402.00
Preferred Stock (Carrying Value)
0.30
0.30
0.30
0.30
0.30

About Agenus

View Profile
Address
3 Forbes Road
Lexington Massachusetts 02421
United States
Employees -
Website http://www.agenusbio.com
Updated 07/08/2019
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, Next-gen CTLA-A, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H.